VRNA

Verona Pharma plc

18.14 USD
-0.05 (-0.27%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Verona Pharma plc stock is down -0.93% since 30 days ago. The next earnings date is May 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 March’s closed higher than February. In the last 4 Unusual Options Trades, there were 1 PUT, 3 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
08 Jan 15:09 19 Jul, 2024 17.50 PUT 200 0
09 Jan 14:30 19 Jul, 2024 20.00 CALL 49 142
26 Jan 18:11 20 Sep, 2024 15.00 CALL 94 0
26 Jan 18:12 20 Sep, 2024 15.00 CALL 94 0

About Verona Pharma plc

Verona Pharma plc focuses on development and commercialization of therapies for respiratory diseases with unmet medical needs. Its product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes. Enfentrine is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.